Drug resistance and minimal residual disease in multiple myeloma

Abstract

Great progress has been made in improving survival in multiple myeloma (MM) patients over the last 30 years. New drugs have been introduced and complete responses are frequently seen. However, the majority of MM patients do experience a relapse at a variable time after treatment, and ultimately the disease becomes drug-resistant following therapies. Recently, minimal residual disease (MRD) detection has been introduced in clinical trials utilizing novel therapeutic agents to measure the depth of response. MRD can be considered as a surrogate for both progression-free and overall survival. In this perspective, the persistence of a residual therapy-resistant myeloma plasma cell clone can be associated with inferior survivals. The present review gives an overview of drug resistance in MM, i.e., mutation of β5 subunit of the proteasome; upregulation of pumps of efflux; heat shock protein induction for proteasome inhibitors; downregulation of CRBN expression; deregulation of IRF4 expression; mutation of CRBN, IKZF1, and IKZF3 for immunomodulatory drugs and decreased target expression; complement protein increase; sBCMA increase; and BCMA down expression for monoclonal antibodies. Multicolor flow cytometry, or next-generation flow, and next-generation sequencing are currently the techniques available to measure MRD with sensitivity at 10^-5. Sustained MRD negativity is related to prolonged survival, and it is evaluated in all recent clinical trials as a surrogate of drug efficacy.

Keywords

Multiple myeloma / minimal residual disease / drug resistance / therapy / next-generation flow cytometry

References

[1] Kumar SK,Dispenzieri A.Improved survival in multiple myeloma and the impact of novel therapies.Blood2008;111:2516-20 PMCID:PMC2254544

[2] Brenner H,Pulte D.Recent major improvement in long-term survival of younger patients with multiple myeloma.Blood2008;111:2521-6

[3] Gozzetti A,Papini G.Therapeutic advancements in multiple myeloma.Front Oncol2014;4:241 PMCID:PMC4154387

[4] Ocio EM,Rajkumar SV.New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).Leukemia2014;28:525-42 PMCID:PMC4143389

[5] Gozzetti A.Novel agents in CNS myeloma treatment.Cent Nerv Syst Agents Med Chem2014;14:23-7

[6] Usmani SZ,Plesner T.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.Blood2016;128:37-44

[7] Jurczyszyn A,Hungria V.Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.Leuk Lymphoma2016;57:2071-6

[8] Kocoglu MH.Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond.Expert Rev Hematol2020;13:669-86

[9] Chari A,Fay JW.Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.Blood2017;130:974-81

[10] Dimopoulos MA,Boccadoro M.Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.Lancet Oncol2021;22:801-12

[11] Mateos M,Blade J.Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.Lancet2020;395:132-41

[12] Facon T,Plesner T.MAIA Trial InvestigatorsDaratumumab plus lenalidomide and dexamethasone for untreated myeloma.N Engl J Med2019;380:2104-15

[13] Moreau P,Hulin C.Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.Lancet2019;394:29-38

[14] Mohty M,Mateos MV.EMMOS InvestigatorsMultiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study.Clin Lymphoma Myeloma Leuk2018;18:e401-19

[15] Gozzetti A,Lotti F.GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Myeloma Working PartyExtramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.Cancer2012;118:1574-84

[16] Castillo JJ,Brozova L.IgM myeloma: a multicenter retrospective study of 134 patients.Am J Hematol2017;92:746-51

[17] Jurczyszyn A,Davila J.Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.Br J Haematol2018;180:831-9

[18] Rajan AM.Interpretation of cytogenetic results in multiple myeloma for clinical practice.Blood Cancer J2015;5:e365 PMCID:PMC4635200

[19] Gozzetti A.Fluorescence in situ hybridization: uses and limitations.Semin Hematol2000;37:320-33

[20] Goldman-Mazur S,Castillo JJ.A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.Am J Hematol2020;95:503-9

[21] Keats JJ,Egan JB.Clonal competition with alternating dominance in multiple myeloma.Blood2012;120:1067-76 PMCID:PMC3412330

[22] Davis LN.Emerging therapeutic strategies to overcome drug resistance in multiple myeloma.Cancers (Basel)2021;13:1686 PMCID:PMC8038312

[23] Paiva B,Orfao A.New criteria for response assessment: role of minimal residual disease in multiple myeloma.Blood2015;125:3059-68 PMCID:PMC4513329

[24] Flores-Montero J,Paiva B.Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.Leukemia2017;31:2094-103 PMCID:PMC5629369

[25] Romano A,Parrinello NL,Martello M.Minimal residual disease assessment within the bone marrow of multiple myeloma: a review of caveats, clinical significance and future perspectives.Front Oncol2019;9:699 PMCID:PMC6710454

[26] Gozzetti A,Bacchiarri F.Minimal residual disease in multiple myeloma: state of the art and applications in clinical practice.J Pers Med2020;10:120 PMCID:PMC7565263

[27] Rawstron AC,Beksac M.European Myeloma NetworkReport of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.Haematologica2008;93:431-8

[28] Brooimans RA,van Putten W,Löwenberg B.Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination.Cytometry B Clin Cytom2009;76:18-26

[29] Gupta R,Kumar L,Jain P.Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.Am J Clin Pathol2009;132:728-32

[30] Delgado JA,Moreno C.A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates.J Immunol Methods2017;442:54-8

[31] Loken MR,Fritschle W,Wells DA.Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses.Cytometry B Clin Cytom2009;76:27-36

[32] Yanamandra U.Minimal residual disease analysis in myeloma - when, why and where.Leuk Lymphoma2018;59:1772-84 PMCID:PMC6208356

[33] Bai Y,Chim CS.Molecular detection of minimal residual disease in multiple myeloma.Br J Haematol2018;181:11-26

[34] Yao Q,Orfao A.Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma.Front Oncol2019;9:449 PMCID:PMC6563351

[35] Perrot A,Corre J.Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.Blood2018;132:2456-64 PMCID:PMC6284215

[36] Kumar S,Anderson KC.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.Lancet Oncol2016;17:e328-46

[37] Munshi NC,Anderson KC.A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.Blood Adv2020;4:5988-99 PMCID:PMC7724898

[38] Berger N,Parekh S.Minimal residual disease in multiple myeloma: impact on response assessment, prognosis and tumor heterogeneity.Adv Exp Med Biol2018;1100:141-59

[39] Chauhan D,Mitsiades C.Proteasome inhibitor therapy in multiple myeloma.Mol Cancer Ther2005;4:686-92

[40] Gozzetti A,Candi V,Sirianni S.Second generation proteasome inhibitors in multiple myeloma.Anticancer Agents Med Chem2017;17:920-6

[41] Ciechanover A.The ubiquitin-proteasome proteolytic pathway.Cell1994;79:13-21

[42] Barrio S,Da-Viá M.Spectrum and functional validation of PSMB5 mutations in multiple myeloma.Leukemia2019;33:447-56

[43] Robak P,Szemraj J.Drug resistance in multiple myeloma.Cancer Treat Rev2018;70:199-208

[44] Leung-Hagesteijn C,Cheung G.Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.Cancer Cell2013;24:289-304 PMCID:PMC4118579

[45] Abraham J,Azab AK.The role of P-glycoprotein in drug resistance in multiple myeloma.Leuk Lymphoma2015;56:26-33

[46] Besse A,Rasche L.Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.Leukemia2018;32:391-401 PMCID:PMC5808083

[47] O'Connor R,Meiller J.The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.Cancer Chemother Pharmacol2013;71:1357-68 PMCID:PMC4414393

[48] Kubiczkova L,Sedlarikova L,Sevcikova S.Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.J Cell Mol Med2014;18:947-61 PMCID:PMC4508135

[49] Baranowska K,Starheim KK.Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.Oncotarget2016;7:70845-56 PMCID:PMC5342593

[50] Xu H,Song S.Exosome-transmitted PSMA3 and PSMA3-AS1 promote proteasome inhibitor resistance in multiple myeloma.Clin Cancer Res2019;25:1923-35

[51] Mitsiades CS,McMullan CJ.Antimyeloma activity of heat shock protein-90 inhibition.Blood2006;107:1092-100 PMCID:PMC1895907

[52] Kuhn DJ,Jones RJ.Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.Blood2012;120:3260-70 PMCID:PMC3476538

[53] Stessman HA,Sarver A.Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.Mol Cancer Ther2013;12:1140-50 PMCID:PMC4076840

[54] Richardson P,Anderson K.Thalidomide in multiple myeloma.Biomed Pharmacother2002;56:115-28

[55] Lopez-Girona A,Ito T.Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.Leukemia2012;26:2326-35 PMCID:PMC3496085

[56] Chamberlain PP,Miller K.Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.Nat Struct Mol Biol2014;21:803-9

[57] Hu S,Yan H.Design, synthesis and biological evaluation of Lenalidomide derivatives as tumor angiogenesis inhibitor.Bioorg Med Chem Lett2017;27:4075-81

[58] Kortüm KM,Hanafiah NH.Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.Blood2016;128:1226-33 PMCID:PMC5524534

[59] Bertrand E,Manier S.Role of IRF4 in resistance to immunomodulatory (IMid) compounds^® in Waldenström's macroglobulinemia.Oncotarget2017;8:112917-27 PMCID:PMC5762562

[60] Haertle L,Munawar U.Cereblon enhancer methylation and IMiD resistance in multiple myeloma.Blood2021;138:1721-6 PMCID:PMC8569411

[61] Lokhorst HM,Laubach JP.Targeting CD38 with daratumumab monotherapy in multiple myeloma.N Engl J Med2015;373:1207-19

[62] Dimopoulos MA,Nahi H.POLLUX InvestigatorsDaratumumab, lenalidomide, and dexamethasone for multiple myeloma.N Engl J Med2016;375:1319-31

[63] Palumbo A,Weisel K.CASTOR InvestigatorsDaratumumab, bortezomib, and dexamethasone for multiple myeloma.N Engl J Med2016;375:754-66

[64] Lonial S,Palumbo A.ELOQUENT-2 InvestigatorsElotuzumab therapy for relapsed or refractory multiple myeloma.N Engl J Med2015;373:621-31

[65] Dimopoulos M,Mateos M.Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.Lancet2020;396:186-97

[66] Nijhof IS,van Velzen J.CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.Blood2016;128:959-70

[67] Varga C,Ghobrial IM.Current use of monoclonal antibodies in the treatment of multiple myeloma.Br J Haematol2018;181:447-59

[68] de Weers M,van der Veer MS.Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.J Immunol2011;186:1840-8

[69] Overdijk MB,Bögels M.Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.MAbs2015;7:311-21 PMCID:PMC4622648

[70] Pick M,Goldschmidt N.Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.Eur J Haematol2018;100:494-501

[71] Cho SF,Xing L.BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma.Cancers (Basel)2020;12:1473 PMCID:PMC7352710

[72] Nijhof IS,Lokhorst HM.Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.Leukemia2015;29:2039-49

[73] Gupta VA,Conage-Pough JE.Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.Blood2017;129:1969-79 PMCID:PMC5383873

[74] Ria R.Bone marrow stromal cells-induced drug resistance in multiple myeloma.Int J Mol Sci2020;21:613 PMCID:PMC7013615

[75] Cencini E,Sicuranza A,Bocchia M.The role of tumor-associated macrophages in hematologic malignancies.Cancers (Basel)2021;13:3597 PMCID:PMC8304632

[76] Beider K,Leiba M.Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype.Oncotarget2014;5:11283-96 PMCID:PMC4294328

[77] Zheng Y,Wang S.Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.Blood2009;114:3625-8 PMCID:PMC2766678

[78] Zheng Y,Qian J.PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.Leukemia2013;27:702-10 PMCID:PMC3652581

[79] Kim J,Dollar BA.Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.Br J Haematol2012;158:336-46 PMCID:PMC3395762

[80] Scavelli C,Cirulli T.Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.Oncogene2008;27:663-74

[81] Ribatti D.The role of monocytes-macrophages in vasculogenesis in multiple myeloma.Leukemia2009;23:1535-6

[82] De Beule N,Maes K.Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.J Pathol2017;241:534-46

[83] Cencini E,Bocchia M.Prognostic role of M2 tumour-associated macrophages in lymphoproliferative disorders.J Pathol2017;242:511-2

[84] Wang H,Xia ZJ.High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens.J Cancer2019;10:3239-45 PMCID:PMC6603386

[85] Andersen MN,Rødgaard-Hansen S,Abildgaard N.The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): implications in multiple myeloma.Leuk Res2015;39:971-5

[86] Suyanı E,Akyürek N.Tumor-associated macrophages as a prognostic parameter in multiple myeloma.Ann Hematol2013;92:669-77

[87] Chen X,Zhang W.Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma.Oncotarget2017;8:112685-96 PMCID:PMC5762541

[88] Panchabhai S,Ahmann G,Mantei J.Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma.Leukemia2016;30:951-4

[89] Andersen MN,Maniecki MB,Andersen NF.Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.Eur J Haematol2014;93:41-7

[90] Landgren O.New developments in diagnosis, prognosis, and assessment of response in multiple myeloma.Clin Cancer Res2016;22:5428-33 PMCID:PMC5587183

[91] Lionetti M.Utilizing next-generation sequencing in the management of multiple myeloma.Expert Rev Mol Diagn2017;17:653-63

[92] Munshi NC,Rawstron AC.Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis.JAMA Oncol2017;3:28-35 PMCID:PMC5943640

[93] Paiva B,Vidriales MB.Spanish Myeloma Group/Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study GroupsPhenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.Blood2016;127:1896-906

[94] Goicoechea I,Cedena MT.Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.Blood2021;137:49-60

[95] Cavo M,Patriarca F.Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.Lancet2010;376:2075-85

[96] Tacchetti P,Patriarca F.Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.Lancet Haematology2020;7:e861-73

[97] Ladetto M,Ferrero S.Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.J Clin Oncol2010;28:2077-84

[98] Attal M,Hulin C.IFM 2009 StudyLenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.N Engl J Med2017;376:1311-20

[99] Jasielec JK,Raje N.Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.Blood2020;136:2513-23 PMCID:PMC7714092

[100] Voorhees PM,Reeves B.Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN.Blood Adv2021;5:1092-6 PMCID:PMC7903234

[101] Laubach JP,Sborov DW.Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of griffin after 24 months of maintenance.Blood2021;138:79

[102] San Miguel JF, Schlag R, Khuageva NK, et al; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.N Engl J Med2008;359:906-17

[103] Benboubker L,Dispenzieri A.FIRST Trial TeamLenalidomide and dexamethasone in transplant-ineligible patients with myeloma.N Engl J Med2014;371:906-17

[104] Facon T,Dispenzieri A.Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.Blood2018;131:301-10 PMCID:PMC5774211

[105] Durie BGM,Sexton R.Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).Blood Cancer J2020;10:53 PMCID:PMC7214419

[106] Gozzetti A,Bacchiarri F.DART4MM: daratumumab as consolidation therapy in patients who already achieved optimal response/MRD positivity by next generation flow (NGF): preliminary results of a phase 2 multicenter study.Clin Lymphoma Myeloma Leuk2019;19:e161-2

[107] Gozzetti A,Sammartano V.Long-term safety of rapid daratumumab infusions in multiple myeloma patients.Front Oncol2020;10:570187 PMCID:PMC7783633